Frontlight ResearchEarly access
Liver and biliary tract cancer trials in China
616 trials · From ClinicalTrials.gov, checked 16 November 2026. Ask the study team whether a trial fits you.
- Phase 2Taking peopleEfficacy and Safety of Postoperative Concurrent Chemoradiotherapy for Extrahepatic Cholangiocarcinoma and Gallbladder Carcinoma: A Multicenter Prospective Phase II Study
- Where
- Beijing
- Age
- 18 years to 80 years
- People
- 92
- Run by
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
See details and how to joinNCT07636824 - No phaseTaking peopleTACE and/or HAIC Combined With Molecular-targeted Therapy and Immunotherapy for HCC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 120
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT07658833 - Phase 2Not yet taking people in ChinaYttrium-90 Carbon Microsphere Radioembolization in Previously Treated Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 20
- Run by
- Second Affiliated Hospital of Guangzhou Medical University
See details and how to joinNCT07657273 - Phase 2Taking peopleA Trial of Apatinib and Adebrelimab in Combination With Chemotherapy in Patients With Unresectable ICC
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 38
- Run by
- Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
See details and how to joinNCT06925516 - Phase 1/2Taking peopleA Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
- Where
- Beijing, Bengbu, Changchun, Fuzhou, Guangzhou, Hangzhou, Harbin, Hefei, Hong Kong, Nanchang, Nanjing, Nanning, Shanghai, Shenyang, Tianjin, Zhengzhou
- Age
- 18 years to 75 years
- People
- 30
- Run by
- Huahui Health
See details and how to joinNCT07547553 - No phaseTaking peoplePrediction Model for MINS After Major Hepatobiliary Surgery
- Where
- Beijing, Chongqing, Qingdao, Shandong, Zhuhai
- Age
- 18 years to 85 years
- People
- 1,800
- Run by
- Beijing Tsinghua Chang Gung Hospital
See details and how to joinNCT07335042 - Phase 1/2Taking peopleDual-Target HER2/CEA CAR-NK Cells in Advanced Biliary Tract Cancer
- Where
- Shenzhen
- Age
- 18 years and over
- People
- 30
- Run by
- Beijing Biotech
See details and how to joinNCT07641036 - Phase 2Taking peopleA Study of BL-B01D1 Monotherapy, BL-B01D1 in Combination With Lenvatinib, BL-B01D1 in Combination With PD-1 Monoclonal Antibody, and BL-B01D1 in Combination With PD-1 Monoclonal Antibody and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 74
- Run by
- Sichuan Baili Pharmaceutical Co., Ltd.
See details and how to joinNCT06986785 - No phaseTaking peopleA Multicenter Prospective Study on the Performance of Spectral CT for Evaluating Treatment Response After TACE in Hepatocellular Carcinoma
- Where
- Nanjing
- Age
- 18 years to 75 years
- People
- 121
- Run by
- Zhongda Hospital
See details and how to joinNCT07351669 - No phaseTaking peopleConstruction and Clinical Validation of a Predictive Model for Postoperative Adjuvant Therapy in Hepatocellular Carcinoma Based on Whole-Slide Digital Pathological Images and Deep Learning
- Where
- Hangzhou
- Age
- 18 years and over
- People
- 11,000
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07417800 - Phase 2Not yet taking people in ChinaEfficacy and Safety of SBRT Plus Gemcitabine, Cisplatin, and Sintilimab as First-Line Treatment for Unresectable Biliary Tract Cancer
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 123
- Run by
- Eastern Hepatobiliary Surgery Hospital
See details and how to joinNCT07638501 - No phaseTaking peopleAdjuvant Therapy for High-Risk Intrahepatic Cholangiocarcinoma: A Real-World Study
- Where
- Beijing
- Age
- 18 years and over
- People
- 90
- Run by
- Peking Union Medical College Hospital
See details and how to joinNCT07640048 - Phase 2Not yet taking people in ChinaA Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
- Where
- Beijing, Harbin
- Age
- 18 years to 80 years
- People
- 227
- Run by
- GV20 Therapeutics
See details and how to joinNCT07623642 - No phaseTaking peopleProspective Clinical Database Construction for Liver Cancer Diagnosis and Treatment
- Where
- Wuhan
- Age
- 18 years and over
- People
- 800
- Run by
- Tongji Hospital
See details and how to joinNCT07587216 - Phase 2/3Taking peopleTrop2-targeted immunoPET Imaging of Solid Tumors
- Where
- Shanghai
- Age
- 18 years to 75 years
- People
- 400
- Run by
- RenJi Hospital
See details and how to joinNCT06851663 - Phase 1Taking peopleSafety and Efficacy of CD160-Enhanced Autologous Antigen-Specific T-Cells (BTC-Ag-T) in Advanced Biliary Tract Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 18
- Run by
- Shanghai Zhongshan Hospital
See details and how to joinNCT07614061 - Phase 2Taking peopleConversion Therapy With FOLFOX-HAIC Plus Lenvatinib And Tislelizumab For Hepatocellular Carcinoma With Vp3 Portal Vein Tumor Thrombus
- Where
- Shenyang
- Age
- 18 years to 80 years
- People
- 38
- Run by
- First Hospital of China Medical University
See details and how to joinNCT07483359 - No phaseTaking peopleEfficacy and Safety of SIRT-Y90 in Combination With Atezo + Bev for Unresectable Hepatocellular Carcinoma
- Where
- Xi’an
- Age
- 18 years and over
- People
- 50
- Run by
- Air Force Military Medical University, China
See details and how to joinNCT07610551 - No phaseTaking peopleEarly-stage Detection of Liver Cancer by Proteins in Peripheral Blood
- Where
- Hangzhou
- Age
- 18 years to 75 years
- People
- 600
- Run by
- Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06544083 - Early phase 1Taking peopleCDH17 CAR-T Therapy in Advanced Malignant Solid Tumors
- Where
- Hangzhou
- Age
- 18 years to 70 years
- People
- 36
- Run by
- Zhejiang University
See details and how to joinNCT06937567 - Phase 3Taking peopleHAIC vs. TACE Combined With Sintilimab and Bevacizumab for Intermediate HCC (Beyond Up-To-Seven)
- Where
- Guangzhou
- Age
- 18 years and over
- People
- 300
- Run by
- Binkui Li
See details and how to joinNCT07594340 - No phaseTaking peopleChina Metastatic Liver Cancer Clinical Registry Cohort Database
- Where
- Bengbu, Hefei, Qingdao
- Age
- 18 years to 80 years
- People
- 2,000
- Run by
- Anhui Provincial Hospital
See details and how to joinNCT07602504 - Phase 1Taking peopleTo Evaluate the Safety, Tolerability, and Preliminary Efficacy of XH001 Injection as Adjuvant Therapy in Patients With High-risk Recurrent Solid Tumors
- Where
- Beijing
- Age
- 18 years to 70 years
- People
- 48
- Run by
- Shenzhen Xinhe Biomedical
See details and how to joinNCT07594964 - Phase 2Taking peopleGemcitabine Hydrochloride, Cisplatin, Nab-Paclitaxel, and Durvalumab in Treating Patients With Locally Advanced or Metastatic Gallbladder Cancer
- Where
- Shanghai
- Age
- 18 years and over
- People
- 33
- Run by
- Fudan University
See details and how to joinNCT06591650 - Phase 1Taking peopleAn Open-Label, Phase I Clinical Trial of Super CAR-T With GPC3-Positive Advanced Hepatocellular Carcinoma
- Where
- Guangzhou
- Age
- 18 years to 75 years
- People
- 15
- Run by
- Guangzhou FineImmune Biotechnology Co., LTD.
See details and how to joinNCT07493044